Modern Inc said data from the late-stage trial of its COVID-19 vaccine suggests it could prevent some asymptomatic infections as soon as the first dose of the shot is given.
The vaccine manufacturer said in information documents it submitted to the U.S. Food and Drug Administration, released Tuesday, that it had not yet completed its full analysis of the effectiveness against asymptomatic infection.
However, it said 38 test participants in the placebo arm of its trial tested positive for COVID-19 without showing symptoms during their second dose. This nearly tripled the number in the vaccine arm of the trial, where there were 14 positive tests from asymptomatic people.
This story was published by a wireless agency with no modifications to the text.